Investors never know what to expect for Ceradyne
What analysts say:
- Buy, sell, or hold?: Analysts think investors should stand pat on Ceradyne with three of five analysts rating it hold. While analysts still rate the stock a hold, they are a little more optimistic about it compared to three months ago.
- Revenue Forecasts: On average, analysts predict $120.1 million in revenue this quarter. That would represent a decline of 20% from the year-ago quarter.
- Wall Street Earnings Expectations: The average analyst estimate is earnings of $0.36 per share. Estimates range from $0.25 to $0.45.
What our community says:
CAPS All-Stars are strongly supporting the stock, with 97.9% granting it an "outperform" rating. The greater community is in line with the All-Stars, as 97.3% give it a rating of "outperform." With just three posts in the past month, Fools have kept relatively quiet about Ceradyne despite their generally positive feelings towards the stock. Ceradyne has a bullish CAPS rating of five out of five stars that is about on par with Fool community assessment.
Management:
Ceradyne's profit has risen year-over-year by an average of more than threefold over the past five quarters.
Quarter | Q4 | Q3 | Q2 | Q1 |
Gross Margin | 32.6% | 36.3% | 36.4% | 38.7% |
Operating Margin | 25.4% | 20.8% | 20.3% | 23.7% |
Net Margin | 16.1% | 13.8% | 13.2% | 15.7% |
For all our Ceradyne-specific analysis, including earnings and beyond, add Ceradyne to My Watchlist.